TY - JOUR
T1 - Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure
T2 - A systematic review
AU - Ganesan, Anand N.
AU - Brooks, Anthony G.
AU - Roberts-Thomson, Kurt C.
AU - Lau, Dennis H.
AU - Kalman, Jonathan M.
AU - Sanders, Prashanthan
N1 - Funding Information:
Dr. Ganesan is supported by a Cardiovascular Lipid Research Grant from Pfizer Australia . Drs. Brooks, Roberts-Thomson, and Sanders are supported by the National Heart Foundation of Australia. Dr. Lau is supported by a Postdoctoral Fellowship from the National Health and Medical Research Council of Australia. Dr. Roberts-Thomson has served on the advisory board of St. Jude Medical. Dr. Sanders has received lecture fees from St. Jude Medical, Bard Electrophysiology, Biosense-Webster, Medtronic, and Merck; research funding from St. Jude Medical, Bard Electrophysiology, Biosense-Webster, and Medtronic; and is on the advisory board for St. Jude Medical, Bard Electrophysiology, Biosense-Webster, Medtronic, and Merck. Dr. Kalman has received unrestricted research grants from St. Jude Medical and Medtronic .
PY - 2012/2/21
Y1 - 2012/2/21
N2 - Objectives: The aim of this study was to systematically review the medical literature to evaluate the impact of AV nodal ablation in patients with heart failure and coexistent atrial fibrillation (AF) receiving cardiac resynchronization therapy (CRT). Background: CRT has a substantial evidence base in patients in sinus rhythm with significant systolic dysfunction, symptomatic heart failure, and prolonged QRS duration. The role of CRT is less well established in AF patients with coexistent heart failure. AV nodal ablation has recently been suggested to improve outcomes in this group. Methods: Electronic databases and reference lists through September 15, 2010, were searched. Two reviewers independently evaluated citation titles, abstracts, and articles. Studies reporting the outcomes after AV nodal ablation in patients with AF undergoing CRT for symptomatic heart failure and left ventricular dyssynchrony were selected. Data were extracted from 6 studies, including 768 CRT-AF patients, composed of 339 patients who underwent AV nodal ablation and 429 treated with medical therapy aimed at rate control alone. Results: AV nodal ablation in CRT-AF patients was associated with significant reductions in all-cause mortality (risk ratio: 0.42 [95% confidence interval: 0.26 to 0.68]), cardiovascular mortality (risk ratio: 0.44 [95% confidence interval: 0.24 to 0.81]), and improvement in mean New York Heart Association functional class (risk ratio: 0.52 [95% confidence interval: 0.87 to 0.17]). Conclusions: AV nodal ablation was associated with a substantial reduction in all-cause mortality and cardiovascular mortality and with improvements in New York Heart Association functional class compared with medical therapy in CRT-AF patients. Randomized controlled trials are warranted to confirm the efficacy and safety of AV nodal ablation in this patient population.
AB - Objectives: The aim of this study was to systematically review the medical literature to evaluate the impact of AV nodal ablation in patients with heart failure and coexistent atrial fibrillation (AF) receiving cardiac resynchronization therapy (CRT). Background: CRT has a substantial evidence base in patients in sinus rhythm with significant systolic dysfunction, symptomatic heart failure, and prolonged QRS duration. The role of CRT is less well established in AF patients with coexistent heart failure. AV nodal ablation has recently been suggested to improve outcomes in this group. Methods: Electronic databases and reference lists through September 15, 2010, were searched. Two reviewers independently evaluated citation titles, abstracts, and articles. Studies reporting the outcomes after AV nodal ablation in patients with AF undergoing CRT for symptomatic heart failure and left ventricular dyssynchrony were selected. Data were extracted from 6 studies, including 768 CRT-AF patients, composed of 339 patients who underwent AV nodal ablation and 429 treated with medical therapy aimed at rate control alone. Results: AV nodal ablation in CRT-AF patients was associated with significant reductions in all-cause mortality (risk ratio: 0.42 [95% confidence interval: 0.26 to 0.68]), cardiovascular mortality (risk ratio: 0.44 [95% confidence interval: 0.24 to 0.81]), and improvement in mean New York Heart Association functional class (risk ratio: 0.52 [95% confidence interval: 0.87 to 0.17]). Conclusions: AV nodal ablation was associated with a substantial reduction in all-cause mortality and cardiovascular mortality and with improvements in New York Heart Association functional class compared with medical therapy in CRT-AF patients. Randomized controlled trials are warranted to confirm the efficacy and safety of AV nodal ablation in this patient population.
KW - atrial fibrillation
KW - biventricular pacing
KW - cardiac resynchronization
KW - heart failure
KW - systematic review
UR - http://www.scopus.com/inward/record.url?scp=84856834043&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2011.10.891
DO - 10.1016/j.jacc.2011.10.891
M3 - Article
C2 - 22340263
AN - SCOPUS:84856834043
SN - 0735-1097
VL - 59
SP - 719
EP - 726
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 8
ER -